Dupilumab significantly improves atopic dermatitis in children aged 6-11 years: results from a phase III trial (LIBERTY AD PEDS)

被引：0
|
作者：
Paller, A. S. [1 ]
Siegfried, E. C. [2 ,3 ]
Gooderham, M. [4 ,5 ]
Beck, L. A. [6 ]
Boguniewicz, M. [7 ,8 ]
Sher, L. [9 ]
Weisman, J. [10 ]
Staudinger, H. W. [11 ]
Sun, X. [12 ]
Shumel, B. [12 ]
机构：
[1] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA
[2] St Louis Univ, St Louis, MO 63103 USA
[3] Cardinal Glennon Childrens Hosp, St Louis, MO USA
[4] SKiN Ctr Dermatol, Peterborough, ON, Canada
[5] Queens Univ, Kingston, ON, Canada
[6] Univ Rochester, Med Ctr, Rochester, NY 14642 USA
[7] Natl Jewish Hlth, Denver, CO USA
[8] Univ Colorado, Sch Med, Denver, CO USA
[9] Peninsula Res Associates, Rolling Hills Estates, CA USA
[10] Adv Med Res PC, Atlanta, GA USA
[11] Sanofi, Cambridge, MA USA
[12] Regeneron Pharmaceut Inc, 777 Old Saw Mill River Rd, Tarrytown, NY 10591 USA
来源：
BRITISH JOURNAL OF DERMATOLOGY | 2020年 / 183卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
P50
引用
收藏
页码：E121 / E121
页数：1
相关论文
共 50 条
  • [1] Dupilumab in children aged ≥6 to <12 years significantly improves severe atopic dermatitis: results from phase 3 trial (LIBERTY AD PEDS)
    Gooderham, M.
    Boguniewicz, M.
    Sher, L.
    Weisman, J.
    Bansal, A.
    Staudinger, H. W.
    Worrell, R.
    Patel, N.
    Graham, N. M. H.
    Ruddy, M.
    Sun, X.
    Beazley, B.
    Shumel, B.
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2021, 62 : 59 - 60
  • [2] RAPID IMPROVEMENT IN ITCH IN CHILDREN AGED 6-11 YEARS WITH SEVERE ATOPIC DERMATITIS TREATED WITH DUPILUMAB: ANALYSIS FROM THE LIBERTY AD PEDS PHASE 3 TRIAL
    Paller, Amy S.
    Park, Young L.
    Lee, Dong H.
    Ahn, Jiyoung
    Yosipovitch, Gil
    Chen, Zhen
    Lee, Joo H.
    Prescilla, Randy
    Rossi, Ana B.
    Delevry, Dimittri
    ACTA DERMATO-VENEREOLOGICA, 2021, 101 : 61 - 61
  • [3] Dupilumab Was Well Tolerated and Significantly Improved Atopic Dermatitis in Children Aged ≥ 6 to < 12 Years: Results From the LIBERTY AD PEDS Phase 3 Trial
    Marcoux, Danielle
    Wu, Jashin J.
    Shumel, Brad
    Ohya, Yukihiro
    Zhang, Annie
    Chen, Zhen
    PEDIATRICS, 2021, 147 (03)
  • [4] Rapid and sustained improvement in itch in children aged 6-11 years with severe atopic dermatitis (AD) treated with dupilumab: analysis from the LIBERTY AD PEDS phase 3 trial
    Yosipovitch, Gil
    Silverberg, Jonathan I.
    Wu, Jashin J.
    Chen, Zhen
    Abramova, Alvina
    Prescilla, Randy
    ALLERGY AND ASTHMA PROCEEDINGS, 2022, 43 (01) : 89 - 89
  • [5] Rapid and sustained improvement in Itch in children aged 6-11 years with severe atopic dermatitis treated with dupilumab: Analysis from the LIBERTY AD PEDS phase 3 trial
    Paller, A. S.
    Weidinger, S.
    Yosipovitch, G.
    Silverberg, J., I
    Wu, J. J.
    Bastian, M.
    Chen, Z.
    Prescilla, R.
    Rossi, A. B.
    Delevry, D.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2021, 19 : 97 - 97
  • [6] Laboratory safety of dupilumab in paediatric patients aged ≥ 6 to < 12 years with severe atopic dermatitis: results from a phase III trial (LIBERTY AD PEDS)
    Wollenberg, A.
    Thaci, D.
    Cork, M. J.
    Arkwright, P. D.
    Gooderham, M.
    Sun, X.
    Vakil, J.
    Khokhar, F. A.
    BRITISH JOURNAL OF DERMATOLOGY, 2021, 185 (03) : E122 - E123
  • [7] Rapid and sustained improvement in itch in children aged 6 11 years with severe atopic dermatitis (AD) treated with dupilumab: Analysis from the LIBERTY AD PEDS phase 3 trial
    Paller, Amy S.
    Siegfried, Elaine C.
    Yosipovitch, Gil
    Silverberg, Jonathan I.
    Wu, Jashin J.
    Chen, Zhen
    Prescilla, Randy
    Rossi, Ana B.
    Delevry, Dimittri
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB140 - AB140
  • [8] Dupilumab for atopic dermatitis in children aged ≥6 to <12 years in phase 3 LIBERTY AD PEDS trial: Analysis by baseline weight
    Paller, A. S.
    Siegfried, E. C.
    Beck, L. A.
    O'Malley, J. T.
    Shumel, B.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2020, 140 (07) : B9 - B9
  • [9] Laboratory Safety of Dupilumab in Patients Aged 6-11 Years with Severe Atopic Dermatitis: Results from a Phase III Clinical Trial
    Paller, Amy S.
    Wollenberg, Andreas
    Siegfried, Elaine
    Thaci, Diamant
    Cork, Michael J.
    Arkwright, Peter D.
    Gooderham, Melinda
    Sun, Xian
    O'Malley, John T.
    Khokhar, Faisal A.
    Vakil, Jignesh
    Bansal, Ashish
    Rosner, Karli
    Shumel, Brad
    Levit, Noah A.
    PEDIATRIC DRUGS, 2021, 23 (05) : 515 - 527
  • [10] LABORATORY SAFETY OF DUPILUMAB IN PEDIATRIC PATIENTS AGED ≥6-<12 YEARS WITH SEVERE ATOPIC DERMATITIS: RESULTS FROM A PHASE 3 TRIAL (LIBERTY AD PEDS)
    Wollenberg, Andreas
    Thaci, Diamant
    Cork, Michael J.
    Arkwright, Peter D.
    Gooderham, Melinda
    Sun, Xian
    O'Malley, John T.
    Khokhar, Faisal A.
    Bansal, Ashish
    Shumel, Brad
    ACTA DERMATO-VENEREOLOGICA, 2021, 101 : 59 - 59
12345